Nonlinear analysis for proposing limit state criteria of reinforced concrete road bridge superstructures

In the research of long-time operating road bridge superstructures, it should note that when the internal forces in the beam elements reach specific values, the stiffness of the cross-section of these elements should decrease. Besides that, if there are damaged places in the beam-element of the road bridge superstructures, the element could not work normally, and the redistribution of internal forces between elements in the whole system would happen. This phenomenon was not taken into account in the initial design calculation. In practice, it shows that many road bridges are subjected to greater loads than the calculated loads in the design process, but they still normally operate. This article proposes the other limit state criteria in evaluating the load capacity reserve of road-bridge superstructures using nonlinear analysis based on nonlinear deformational models of modern construction codes. The proposed calculation procedure is established to explain the load capacity reserve of long-time operating road bridge superstructures in the case of the lack of experimental evaluation. From the obtained results, the suitable limit state criteria for road bridge superstructures are suggested, and the conclusions about the accuracy of the proposed approach of nonlinear structural analysis are recommended

Geometrically nonlinear buckling analysis of truss with length imperfection subjected to mechanical and thermal load using hybrid FEM

This paper presents a novel hybrid FEM-based approach to establish the mathematical model for solving the nonlinear buckling problem of truss systems with length imperfection under mechanical and thermal load. due to constant temperature change-based hybrid FEM. The proposed approach deals with establishing hybrid types of truss elements, including perfect truss elements without thermal deformation and truss elements with length imperfection and thermal deformation. The equilibrium equation of both truss elements is established based on compatibility relationships considering geometric nonlinearity. The hybrid global equilibrium equations of truss systems are developed by assembling constructed perfect truss elements without thermal deformation and truss elements with length imperfection and thermal deformation. The incremental-iterative algorithm based on the arc-length method is used to establish calculation programs to solve the hybrid global equilibrium equation for investigating the geometrically nonlinear buckling behavior of the truss system. The numerical test is presented to investigate the buckling and post-buckling behavior of truss systems having some elements with length imperfection under thermal and mechanical load

Synthesis of cuprous oxide nanocubes combined with chitosan nanoparticles and its application to p-nitrophenol degradation

For the first time, cuprous oxide nanocubes (Cu2O NCBs) were successfully combined with chitosan nanoparticles (CS NPs) to generate Cu2O NCBs/CS NPs composites material with highly optical property and photocatalytic activity using a simple and eco-friendly synthetic approach at room temperature for 30 min. The synthesized Cu2O NCBs NPs/CS NPs were determined characterizations by Ultraviolet-visible spectroscopy (UV-vis), Fourier transform infrared spectroscopy (FTIR), X – ray Diffraction (XRD),  Transmission Electron Microscope (TEM) and Energy-dispersive X-ray spectroscopy (EDX). Results show that the Cu2O NCBs/CS NPs composites have an average particle size of ~3-5 nm; in which, Cu2O has the form of nanocubes (Cu2O NCBs) with size ~3-4 nm and chitosan nanoparticles with spherical shape (CS NPs) with size ~4-5 nm. In addition, the percent (%) composition of elements present in Cu2O NCBs/CS NPs composites material have been obtained respective: Cu (23.99%), O (38.18%), and C (33.61%). Moreover, Cu2O NCBs/CS NPs composites material was also investigated for photocatalytic activity applied in p-nitrophenol degradation. The obtained results showed that the catalytic capability of Cu2O NCBs/CS NPs for p-nitrophenol reduction reached the highest efficiency >55% in the treatment time of 25 min, and this efficiency was higher than that result of using ZnO@chitosan nanoparticles (ZnO@CS NPs) catalyst under the same conditions for comparison

Adsorption of ciprofloxacin using composite Film from PVA, agarose and maltodextrin

Rintangan antibiotik ialah salah satu masalah yang paling membimbangkan hari ini. Oleh itu, membran komposit telah digunakan secara meluas untuk penyingkiran antibiotik daripada air. Filem PVA/Agarosa/Maltodekstrin telah disintesis dengan tuangan dengan pelbagai nisbah komponen. Ia dinilai untuk ciri melalui kelembapan, keterlarutan, pengembangan dan keputusan BET. Keputusan menunjukkan bahawa filem PVA/Agarosa/Maltodekstrin mempamerkan daya maju terbaik dalam persekitaran akuatik melalui keterlarutan rendah (68.88% ± 0.03), bengkak tinggi (431.77% ± 5.89) dan isi padu liang (0.034969 cm³/g). Kapasiti penjerapan PVA/Agarosa/Maltodekstrin telah diuji untuk beberapa antibiotik seperti Ciprofloksacin, Tetracycline, Oxy-Tetracycline dan Chloramphenicol. Keputusan menunjukkan bahawa Ciprofloksacin telah dikeluarkan oleh filem PVA/Agarosa/Maltodekstrin lebih baik daripada antibiotik lain. Penjerapan antibiotik tertinggi diperoleh pada 20 minit, suhu 30 °C, dos 2 g/L, pH 6 dan kepekatan antibiotik 40 mg/L. Penjerapan Ciprofloksacin telah diramalkan melalui model kinetik dan isoterma penjerapan. Keserasian kinetik Pseudo First Order dan isoterma Dubinin-Radushkevich telah menunjukkan bahawa penjerapan berlaku mengikut mekanisme penjerapan fizikal dengan interaksi elektrostatik pada permukaan bahan. Kapasiti penjerapan maksimum direkodkan pada 4.48 mg/g berdasarkan isoterma Dubinin-Radushkevich

The acceptability of and willingness to pay for a herpes zoster vaccine: A systematic review

Patients, predominantly the elderly, with Herpes Zoster (HZ) not only suffer symptoms of the disease but also bear considerable expenses. This study systematically reviewed the acceptability of and willingness to pay for the HZ vaccine. This review was registered in PROSPERO 2023 (CRD42023403062). We used “acceptance”, “willing to pay”, and “HZ vaccine” (and variations thereof) as keywords in a systematic search for original English research articles published up to April 7, 2023. The search was conducted over Scopus, PubMed, ScienceDirect, Cochrane, and Google Scholar in accordance with PRISMA 2020 guidelines. The inclusion criteria were as follows: studies (1) that mentioned HZ vaccination, (2) related to acceptability or willingness to pay, and (3) with full texts available and peer-reviewed prior to final publication. Grey literature, letters to editors, commentaries, case reports or series, systematic reviews, meta-analyses, articles of poor quality, and articles with ambiguously defined and measured outcome variables were excluded. The Joanna Briggs Institute (JBI) critical appraisal checklist was used to evaluate the methodological quality of the studies. Finally, the search yielded 24 studies, of which 9 were conducted in Asia, 8 in Europe, and 7 in America. General adults or patients aged 50 or older were often the target populations, for whom treatments were accompanied by healthcare providers’ recommendations. The willingness to pay and willingness to accept the vaccine ranged from $8 to$150 and 16.6% to 85.8%, respectively. Compared to the US, Asia and Europe had higher acceptance rates for HZ immunization. The most frequent excuses given for not being vaccinated are side effects, cost, lack of recommendations, anti-vaccination views, ignorance about the HZ vaccine, and the belief that one is not at risk for the disease. National campaigns should be developed to increase public awareness of HZ, and more international research should be conducted to understand the WTA and WTP for HZ immunizations

Comparative Susceptibility of Aedes albopictus and Aedes aegypti to Dengue Virus Infection After Feeding on Blood of Viremic Humans: Implications for Public Health.

Aedes albopictus is secondary to Aedes aegypti as a vector of dengue viruses (DENVs) in settings of endemicity, but it plays an important role in areas of dengue emergence. This study compared the susceptibility of these 2 species to DENV infection by performing 232 direct blood-feeding experiments on 118 viremic patients with dengue in Vietnam. Field-derived A. albopictus acquired DENV infections as readily as A. aegypti after blood feeding. Once infected, A. albopictus permitted higher concentrations of DENV RNA to accumulate in abdominal tissues, compared with A. aegypti. However, the odds of A. albopictus having infectious saliva were lower than the odds observed for A. aegypti (odds ratio, 0.70; 95% confidence interval, .52-.93). These results quantitate the susceptibility of A. albopictus to DENV infection and will assist parameterization of models for predicting disease risk in settings where A. albopictus is present

Assessing the efficacy and safety of magnesium sulfate for management of autonomic nervous system dysregulation in Vietnamese children with severe hand foot and mouth disease.

BACKGROUND: Brainstem encephalitis is a serious complication of hand foot and mouth disease (HFMD) in children. Autonomic nervous system (ANS) dysregulation and hypertension may occur, sometimes progressing to cardiopulmonary failure and death. Vietnamese national guidelines recommend use of milrinone if ANS dysregulation with Stage 2 hypertension develops. We wished to investigate whether magnesium sulfate (MgSO4) improved outcomes in children with HFMD if used earlier in the evolution of the ANS dysregulation (Stage 1 hypertension). METHODS: During a regional epidemic we conducted a randomized, double-blind, placebo-controlled trial of MgSO4 in children with HFMD, ANS dysregulation and Stage 1 hypertension, at the Hospital for Tropical Diseases in Ho Chi Minh city. Study participants received an infusion of MgSO4 or matched placebo for 72 h. We also reviewed data from non-trial HFMD patients in whom milrinone failed to control hypertension, some of whom received MgSO4 as second line therapy. The primary outcome for both analyses was a composite of disease progression within 72 h - addition of milrinone (trial participants only), need for ventilation, shock, or death. RESULTS: Between June 2014 and September 2016, 14 and 12 participants received MgSO4 or placebo respectively, before the trial was stopped due to futility. Among 45 non-trial cases with poorly controlled hypertension despite high-dose milrinone, 33 received MgSO4 while 12 did not. There were no statistically significant differences in the composite outcome between the MgSO4 and the placebo/control groups in either study (adjusted relative risk (95%CI) of [6/14 (43%) vs. 6/12 (50%)], 0.84 (0.37, 1.92), p = 0.682 in the trial and [1/33 (3%) vs. 2/12 (17%)], 0.16 (0.01, 1.79), p = 0.132 in the observational cohort). The incidence of adverse events was similar between the groups. Potentially toxic magnesium levels occurred very rarely with the infusion regime used. CONCLUSION: Although we could not demonstrate efficacy in these studies, there were no safety signals associated with use of 30-50 mg/kg/hr. MgSO4 in severe HFMD. Intermittent outbreaks of HFMD are likely to continue across the region, and an adequately powered trial is still needed to evaluate use of MgSO4 in controlling hypertension in severe HFMD, potentially involving a higher dose regimen. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01940250 (Registered 22 AUG 2013). Trial sponsor: University of Oxford

Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial

Background Trials of fluoxetine for recovery after stroke report conflicting results. The Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial aimed to show if daily oral fluoxetine for 6 months after stroke improves functional outcome in an ethnically diverse population. Methods AFFINITY was a randomised, parallel-group, double-blind, placebo-controlled trial done in 43 hospital stroke units in Australia (n=29), New Zealand (four), and Vietnam (ten). Eligible patients were adults (aged ≥18 years) with a clinical diagnosis of acute stroke in the previous 2–15 days, brain imaging consistent with ischaemic or haemorrhagic stroke, and a persisting neurological deficit that produced a modified Rankin Scale (mRS) score of 1 or more. Patients were randomly assigned 1:1 via a web-based system using a minimisation algorithm to once daily, oral fluoxetine 20 mg capsules or matching placebo for 6 months. Patients, carers, investigators, and outcome assessors were masked to the treatment allocation. The primary outcome was functional status, measured by the mRS, at 6 months. The primary analysis was an ordinal logistic regression of the mRS at 6 months, adjusted for minimisation variables. Primary and safety analyses were done according to the patient's treatment allocation. The trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12611000774921. Findings Between Jan 11, 2013, and June 30, 2019, 1280 patients were recruited in Australia (n=532), New Zealand (n=42), and Vietnam (n=706), of whom 642 were randomly assigned to fluoxetine and 638 were randomly assigned to placebo. Mean duration of trial treatment was 167 days (SD 48·1). At 6 months, mRS data were available in 624 (97%) patients in the fluoxetine group and 632 (99%) in the placebo group. The distribution of mRS categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio 0·94, 95% CI 0·76–1·15; p=0·53). Compared with patients in the placebo group, patients in the fluoxetine group had more falls (20 [3%] vs seven [1%]; p=0·018), bone fractures (19 [3%] vs six [1%]; p=0·014), and epileptic seizures (ten [2%] vs two [<1%]; p=0·038) at 6 months. Interpretation Oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and epileptic seizures. These results do not support the use of fluoxetine to improve functional outcome after stroke

Penalty function method for geometrically nonlinear buckling analysis of imperfect truss with multi-freedom constraints based on mixed FEM

This paper is concerned with the approach to implementing the Penalty function method for imposing multi-freedom constraints in geometrically nonlinear analysis of imperfect trusses based on mixed finite element formulation. Using a finite element model based on displacement formulation, it is required to incorporate both the dependent boundary relations and initial length imperfection to the nonlinear master stiffness system of equations for solving the geometrically nonlinear problem of imperfect truss with multi-freedom constraints. For decreasing the mathematical complexion of the incorporating process, the author proposes a novel mixed finite truss element considering initial imperfection, used in building the model for solving the geometrically nonlinear problem of truss with multi-freedom constraints. The modified nonlinear stiffness equation is constructed by employing the penalty function method to convert a constrained problem into an unconstrained problem by extremizing the augmented energy function established based on the proposed mixed finite element formulation. For solving the nonlinear equilibrium equation of imperfect trusses with multi-freedom constraints, the incremental equilibrium equation is constructed, and the incremental-iterative algorithm for calculation is established utilizing the arc-length method, used for writing the calculation program for investigating geometrically nonlinear behavior of imperfect truss with multi-freedom constraints. The results of the numerical test show the influence of initial imperfection and choosing weight values on the equilibrium path of the truss

Augmented Lagrangian method for imposing nonlinear multi freedom constraints in static analysis for frames using FEM

This paper focuses on the treatment of nonlinear multi freedom constraints using an augmented Lagrangian method in finite element analysis of frames. The process of imposing boundary constraints is developed by changing the assembly stiffness equation to produce a modified system of equation considering nonlinear multi freedom constraints. For imposing the nonlinear constraints two better methods are the penalty augmentation method and Lagrange multiplier adjunction method. But there are not free of disadvantages. Using penalty method has a disadvantage in the choice appropriate weight values that balance solution accuracy with the violation of constraint conditions. Using the Lagrange multiplier adjunction method requires additional unknowns, and more complicated storage allocation procedures. This research proposes the connection between these methods using the augmented Lagrangian method for imposing the nonlinear multi freedom constraints in finite element analysis of frame. Based on the Newton Raphson method the incremental-iterative algorithm for solving the nonlinear balanced equations is established